Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study.

ABSTRACT:

Objectives

To report the epidemiology, treatments, and outcomes of adult patients admitted to the ICU after cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome.

Design

Retrospective cohort study.

Setting

Nine centers across the U.S. part of the chimeric antigen receptor-ICU initiative.

Patients

Adult patients treated with chimeric antigen receptor T-cell therapy who required ICU admission between November 2017 and May 2019.

Interventions

Demographics, toxicities, specific interventions, and outcomes were collected.

Results

One-hundred five patients treated with axicabtagene ciloleucel required ICU admission for cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome during the study perio

SUBMITTER: Gutierrez C 

PROVIDER: S-EPMC8678137 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature